HLUN B Stock Overview

A biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. More details

HLUN B fundamental analysis
Snowflake Score
Valuation	5/6
Future Growth	1/6
Past Performance	5/6
Financial Health	3/6
Dividends	3/6

Rewards

Trading at 79.7% below our estimate of its fair value

Earnings are forecast to grow 5.95% per year

Earnings grew by 37.2% over the past year

Trading at good value compared to peers and industry

Risk Analysis

Has a high level of debt

Community Narratives

Create a narrative

Narratives bring a range of perspectives from our community.

Analyst Price Target

Consensus Narrative from 12 Analysts

Vyepti's Asian Triumph And Pipeline Advancements Ignite Strong Revenue Growth

Key Takeaways Strong growth of strategic brands, especially Vyepti and Rexulti, is expected to drive substantial revenue increase in Asian and emerging markets. Anticipated regulatory approvals and drug pipeline advancements will positively impact future earnings and long-term growth potential.

View narrative

DKK 51.95

16.9% undervalued

5.82%

Revenue growth p.a.

8 days ago

My Notes

Capture your thoughts, links and company narrative

H. Lundbeck A/S Competitors

ALK-Abelló

CPSE:ALK B

DKK 35.2b

Novo Nordisk

CPSE:NOVO B

DKK 2.7t

Genmab

CPSE:GMAB

DKK 89.1b

ChemoMetec

CPSE:CHEMM

DKK 9.5b

Price History & Performance

Summary of share price highs, lows and changes for H. Lundbeck
Historical stock prices
Current Share Price	DKK 43.20
52 Week High	DKK 49.38
52 Week Low	DKK 31.62
Beta	0.25
1 Month Change	6.40%
3 Month Change	0.98%
1 Year Change	36.11%
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	32.92%

Is H. Lundbeck (CPH:HLUN B) A Risky Investment?

Jan 26

Recent updates

H. Lundbeck (CPH:HLUN B) Has Announced That It Will Be Increasing Its Dividend To DKK0.70

Feb 22

H. Lundbeck A/S Just Missed Earnings - But Analysts Have Updated Their Models

Feb 10

Shareholder Returns

	HLUN B	DK Pharmaceuticals	DK Market
7D	-0.09%	2.0%	0.7%
1Y	36.1%	-23.7%	-15.2%

Return vs Industry: HLUN B exceeded the Danish Pharmaceuticals industry which returned -23.7% over the past year.

Return vs Market: HLUN B exceeded the Danish Market which returned -15.2% over the past year.

Price Volatility

Is HLUN B's price volatile compared to industry and market?
HLUN B volatility
HLUN B Average Weekly Movement	3.9%
Pharmaceuticals Industry Average Movement	5.4%
Market Average Movement	4.7%
10% most volatile stocks in DK Market	10.6%
10% least volatile stocks in DK Market	2.8%

Stable Share Price: HLUN B has not had significant price volatility in the past 3 months compared to the Danish market.

Volatility Over Time: HLUN B's weekly volatility (4%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1915	5,500	Charl van Zyl	www.lundbeck.com

H. Lundbeck A/S, a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company’s principal products include Abilify Maintena/Abilify Maintena for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Northera for the treatment of symptomatic neurogenic orthostatic hypotension; Vyepti for migraine prevention; and Rexulti/Rxulti to treat MDD and schizophrenia. It also provides Azilect for treating Parkinson’s disease; Cipralex/Lexapro for depression; Ebixa to treat dementia; Onfi for epilepsy; Sabril for the treatment of refractory complex partial seizures and infantile spasms; Xenazine for chorea; Deanxit for depression; Cipramil for depression and anxiety; and Cisordinol to treat psychosis.

H. Lundbeck A/S Fundamentals Summary

How do H. Lundbeck's earnings and revenue compare to its market cap?
HLUN B fundamental statistics
Market cap	DKK 42.70b
Earnings (TTM)	DKK 3.14b
Revenue (TTM)	DKK 22.00b

13.6x

P/E Ratio

1.9x

P/S Ratio

Is HLUN B overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
HLUN B income statement (TTM)
Revenue	DKK 22.00b
Cost of Revenue	DKK 4.23b
Gross Profit	DKK 17.77b
Other Expenses	DKK 14.63b
Earnings	DKK 3.14b

Last Reported Earnings

Dec 31, 2024

Next Earnings Date

May 14, 2025

Earnings per share (EPS)	3.17
Gross Margin	80.78%
Net Profit Margin	14.28%
Debt/Equity Ratio	64.7%

How did HLUN B perform over the long term?

See historical performance and comparison

Dividends

1.6%

Current Dividend Yield

26%

Payout Ratio

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/02/06 18:01
End of Day Share Price	2025/02/06 00:00
Earnings	2024/12/31
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

H. Lundbeck A/S is covered by 41 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
null null	ABG Sundal Collier
Peter Ankersen	ABG Sundal Collier
Kamla Singh	AlphaValue

HLUN B Stock Overview

Rewards

Risk Analysis

Vyepti's Asian Triumph And Pipeline Advancements Ignite Strong Revenue Growth

H. Lundbeck A/S Competitors

CPSE:ALK B

DKK 35.2b

CPSE:NOVO B

DKK 2.7t

CPSE:GMAB

DKK 89.1b

CPSE:CHEMM

DKK 9.5b

Price History & Performance

Recent News & Updates

New minor risk - Financial position

H. Lundbeck A/S, Annual General Meeting, Mar 26, 2025

H. Lundbeck A/S Announces Board Changes

H. Lundbeck A/S Announces Positive Results from 12-Month Open-Label Extension of the PACIFIC Trial Evaluating Bexicaserin in Participants with Developmental and Epileptic Encephalopathies

Is H. Lundbeck (CPH:HLUN B) A Risky Investment?

H. Lundbeck A/S (Lundbeck) Announces That the U.S. Food and Drug Administration Plans to Host A Psychopharmacologic Drugs Advisory Committee Meeting to Seek Input on Issues Related to the Supplemental New Drug Application for Brexpiprazole

Recent updates

New minor risk - Financial position

H. Lundbeck A/S, Annual General Meeting, Mar 26, 2025

H. Lundbeck A/S Announces Board Changes

H. Lundbeck A/S Announces Positive Results from 12-Month Open-Label Extension of the PACIFIC Trial Evaluating Bexicaserin in Participants with Developmental and Epileptic Encephalopathies

Is H. Lundbeck (CPH:HLUN B) A Risky Investment?

H. Lundbeck A/S (Lundbeck) Announces That the U.S. Food and Drug Administration Plans to Host A Psychopharmacologic Drugs Advisory Committee Meeting to Seek Input on Issues Related to the Supplemental New Drug Application for Brexpiprazole

H. Lundbeck A/S to Report First Half, 2025 Results on Aug 20, 2025

H. Lundbeck A/S' (CPH:HLUN B) Price In Tune With Earnings

H. Lundbeck A/S Announces Positive Results from the Resolve Trial

H. Lundbeck Initiates a Phase III Trial with Amlenetug for the Treatment of Multiple System Atrophy

We Think H. Lundbeck's (CPH:HLUN B) Solid Earnings Are Understated

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

H. Lundbeck A/S Raises Earnings Guidance for the Year 2024

H. Lundbeck A/S Announces Positive Results from Phase III Pivotal Trial (Sunrise) of Vyepti® (Eptinezumab) in Migraine Prevention

H. Lundbeck (CPH:HLUN B) Seems To Use Debt Quite Sensibly

H. Lundbeck A/S (CPSE:HLUN B) signed an agreement to acquire Longboard Pharmaceuticals, Inc. (NasdaqGM:LBPH) for $2.3 billion.

H. Lundbeck A/S (CPSE:HLUN B) signed an agreement to acquire Longboard Pharmaceuticals, Inc. (NasdaqGM:LBPH) for $2.3 billion.

H. Lundbeck A/S Initiates Clinical Trial in Immunology for Lu Ag22515 in Thyroid Eye Disease

Investors Aren't Entirely Convinced By H. Lundbeck A/S' (CPH:HLUN B) Earnings

H. Lundbeck A/S Presents Results from Two Studies in Multiple System Atrophy at International Congress of Parkinson's Disease and Movement Disorders

Price target increased by 9.4% to kr.45.54

Do H. Lundbeck's (CPH:HLUN B) Earnings Warrant Your Attention?

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Investors Interested In H. Lundbeck A/S' (CPH:HLUN B) Earnings

Lundbeck and Otsuka Announce FDA Acceptance of sNDA Filing for Brexpiprazole in Combination with Sertraline for the Treatment of Adults with Post-Traumatic Stress Disorder

H. Lundbeck A/S Expands Focus on Neurohormonal Dysfunctions with New Cushing's Disease Trial

Lundbeck Presents Innovative First in Human Trial Design of Lu AG13909 for Potential Treatment of Congenital Adrenal Hyperplasia

These 4 Measures Indicate That H. Lundbeck (CPH:HLUN B) Is Using Debt Safely

H. Lundbeck A/S to Report Q4, 2024 Results on Feb 05, 2025

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

H. Lundbeck A/S Provides Earnings Guidance for the Year 2024

H. Lundbeck A/S Appoints Announces the Appointment of Maria Alfaiate as EVP, Commercial and Corporate Strategy, Effective 1 August 2024

Lundbeck and Otsuka submit sNDA for FDA review of brexpiprazole and sertraline combination as potential treatment for PTSD

Otsuka Pharmaceutical Europe Ltd. and H. Lundbeck A/S Announces Approval in the EU for the Maintenance Treatment of Schizophrenia

H. Lundbeck A/S Announces Management Appointments

H. Lundbeck A/S Announces Potential First-In-Class Therapy for Migraine Prevention Enters Advanced Clinical Stage

Upcoming dividend of kr.0.70 per share

H. Lundbeck (CPH:HLUN B) Will Pay A Larger Dividend Than Last Year At DKK0.70

H. Lundbeck A/S Proposes Dividend for the Accounting Year 2023

H. Lundbeck (CPH:HLUN B) Has Announced That It Will Be Increasing Its Dividend To DKK0.70

Key Executive recently bought kr.751k worth of stock

H. Lundbeck A/S Just Missed Earnings - But Analysts Have Updated Their Models

Less than half of directors are independent

H. Lundbeck A/S Appoints Dianne Holto as EVP, People & Organization, Effective from April 1, 2024

Lundbeck Announces Supportive Phase II Results with Lu Af82422 in the Treatment of Multiple System Atrophy from the Amulet Trial

H. Lundbeck A/S to Report Nine Months, 2024 Results on Nov 13, 2024

H. Lundbeck A/S, Annual General Meeting, Mar 20, 2024

H. Lundbeck A/S Announces New Clinical Data Supporting the Efficacy and Tolerability of Lu AG09222 for the Preventive Treatment of Migraine At the International Headache Congress 2023 in Seoul, Korea

Lundbeck and Otsuka Announce Topline Results from Two Phase III Trials of Brexpiprazole as Combination Therapy with Sertraline for the Treatment of Post-Traumatic Stress Disorder in Adults

H. Lundbeck A/S Announces Elise Hauge Executive Vice President, People and Communication Decides to Depart

H. Lundbeck A/S to Report Q4, 2023 Results on Feb 07, 2024

Shareholder Returns

Price Volatility

About the Company

H. Lundbeck A/S Fundamentals Summary

13.6x

1.9x

Earnings & Revenue